Showing 69,341 - 69,360 results of 133,285 for search '(( 2 c decrease ) OR ( 5 ((((step decrease) OR (a decrease))) OR (we decrease)) ))', query time: 1.80s Refine Results
  1. 69341
  2. 69342
  3. 69343
  4. 69344
  5. 69345

    Evaluation of a Dengue NS1 Antigen Detection Assay Sensitivity and Specificity for the Diagnosis of Acute Dengue Virus Infection by Laura L. Hermann (638244)

    Published 2014
    “…In primary infections, the InBios NS1 kit demonstrated a higher sensitivity (98.8%) than in secondary infections (83.5%). …”
  6. 69346

    DataSheet_2_Evidence of a conserved mammalian immunosuppression mechanism in Lutzomyia longipalpis upon infection with Leishmania.pdf by Erich Loza Telleria (8047055)

    Published 2023
    “…In mammalian infections, the Leishmania surface glycoprotein GP63 is one of the inducers of host immune depression, and one of the known effectors is SHP. In L. longipalpis we found a similar effect: a genetically modified strain of Leishmania amazonensis over-expressing the metalloprotease GP63 induced a higher expression of the sand fly SHP indicating that the L. longipalpis SHP and parasite GP63 increased expressions are connected. …”
  7. 69347

    DataSheet_1_Evidence of a conserved mammalian immunosuppression mechanism in Lutzomyia longipalpis upon infection with Leishmania.pdf by Erich Loza Telleria (8047055)

    Published 2023
    “…In mammalian infections, the Leishmania surface glycoprotein GP63 is one of the inducers of host immune depression, and one of the known effectors is SHP. In L. longipalpis we found a similar effect: a genetically modified strain of Leishmania amazonensis over-expressing the metalloprotease GP63 induced a higher expression of the sand fly SHP indicating that the L. longipalpis SHP and parasite GP63 increased expressions are connected. …”
  8. 69348
  9. 69349

    Peritumoral edema measurements. by Eric C. Woolf (755935)

    Published 2015
    “…<p>(A) Representative MRI image of tumor bearing mouse (B) 14 days following tumor implantation, edema was measured via MRI. A 2-fold decrease in peritumoral edema was seen in animals fed KC compared to SD (N = 3; *p < 0.05). …”
  10. 69350

    Table_1_Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization.docx by Changwei Zheng (13928844)

    Published 2022
    “…Here, we try to identify these causal risk factors using a two-sample Mendelian randomization (MR) analysis. …”
  11. 69351

    <i>Lp</i> knockdown significantly impairs oogenesis and affects Vg expression and localization. by Iryna Stryapunina (17867390)

    Published 2024
    “…(B) RT-qPCR of <i>Vg</i> expression levels relative to <i>Rpl19</i> in the fat body of ds<i>LacZ</i> and ds<i>Lp</i> females; samples of ten tissues, four biological replicates (REML variance component analysis: ** = p < 0.01; **** = p < 0.0001; four biological replicates). (C) Western blot quantification from <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1011145#pgen.1011145.g001" target="_blank">Fig 1C</a> showing an accumulation of Vg in the fat body and a decrease of Vg in the ovaries upon <i>Lp</i> knockdown; samples of five tissues, three biological replicates (REML variance component analysis: ** = p < 0.01; **** = p < 0.0001). …”
  12. 69352

    Sample characteristics using MICS 2012 and 2019. by Satyajit Kundu (9078709)

    Published 2025
    “…Hence, we examined the factors contributing to the changes in childhood stunting over time in Bangladesh using a decomposition approach. …”
  13. 69353

    DataSheet_1_Identification and Validation of Novel Immune-Related Alternative Splicing Signatures as a Prognostic Model for Colon Cancer.docx by Yunze Liu (11410635)

    Published 2022
    “…Notably, we identified for the first time that anti-PD-L1 or anti-CTLA-4 antibodies may decrease the OS of specific colon cancer patients in the low-risk group. …”
  14. 69354

    DataSheet_1_Identification and Validation of Novel Immune-Related Alternative Splicing Signatures as a Prognostic Model for Colon Cancer.zip by Yunze Liu (11410635)

    Published 2022
    “…Notably, we identified for the first time that anti-PD-L1 or anti-CTLA-4 antibodies may decrease the OS of specific colon cancer patients in the low-risk group. …”
  15. 69355

    AUROC as a function of aCPT accuracy for the 60% peak gas group for (top left) weighted global efficiency, , (top right) global coherence, , at 11 Hz, (bottom left) the contributio... by Levin Kuhlmann (282293)

    Published 2013
    “…The difference in the median measure value relative to rest is indicated by the the direction of the respective bar (up, increase; down, decrease). Multi-comparison test significance marker (, ) details are the same as for <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0056434#pone-0056434-g005" target="_blank">Figure 5</a>. …”
  16. 69356
  17. 69357
  18. 69358
  19. 69359

    Dose–Risk and Duration–Risk Relationships between Aspirin and Colorectal Cancer: A Meta-Analysis of Published Cohort Studies by Xiaohua Ye (381307)

    Published 2013
    “…The dose-response meta-analysis showed that there was a 20% statistically significant decreased risk of colorectal cancer for 325 mg aspirin per day increment, 18% decreased risk for 7 times aspirin per week increment and 18% decreased risk for 10 years aspirin increment.…”
  20. 69360

    RGD-A-<i>TNF</i> Multiple Dose Study: Patient Data and Tumor Responses by Melissa C. Paoloni (247731)

    Published 2013
    “…<p>FS: fibrosarcoma; OS: osteosarcoma; PNST: peripheral nerve sheath tumor (malignant); SCC: squamous cell carcinoma; S-C MS: subcutaneous myxosarcoma; MLT: multi-lobular tumor; Mel: LN mets: melanoma lymph node metastases; inc.: increase; dec.: decrease; PD: progressive disease; SD: stable disease (shown in yellow); PR: partial response (shown in green); Unevaluable: due to consent withdrawal by the owner, or death or euthanasia before completion of cycle 1</p>*<p>Patient I.D.: dog is identified as participating in study 2 (fixed multiple dose study), followed by patient number (i.e. patient 2.2 is dog 2 in study 2 and so on)</p><p>Cycle 1: dogs received 4 weekly doses of RGD-A-<i>TNF</i>; Cycle 2: dogs received additional 4 weekly doses of RGD-A-<i>TNF</i></p>…”